A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

NCT03057912 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Human Papillomavirus-Related Malignant Neoplasm

Interventions

BIOLOGICAL: TALEN
BIOLOGICAL: CRISPR/Cas9

Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Collaborators

[object Object]